Literature DB >> 9616273

Lung cancer in the elderly.

C Gridelli1, F Perrone, S Monfardini.   

Abstract

Entities:  

Mesh：

Year:  1997        PMID： 9616273     DOI： 10.1016/s0959-8049(97)10050-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  27 in total

1.  Clinical observation of Shuanghuang Shengbai Granule () on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients.

Authors:  Li-Fang Wang; Zhen-Ye Xu; Zhong-Qi Wang; Ming Zhang; Gui-Ying Yan; An-Ji Hou; Hai-Bin Deng; Ji Wu; Xiao-Zhen Zhao; Yi Xiang; Lei Yu
Journal:  Chin J Integr Med       Date:  2016-08-02       Impact factor: 1.978

2.  Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience.

Authors:  U Kefeli; S Kaya; B O Ustaalioglu; A Bilici; A U Kefeli; M E Yildirim; M Seker; B Yilmaz; T Salepci; K Uygun; M Gumus
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

3.  Lung surgery in elderly patients: are we doing enough?

Authors:  Marco Scarci; Roberto Crisci; Fabrizio Minervini
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

4.  Elderly patients with squamous lung carcinoma: faring better or worse?

Authors:  George Pentheroudakis; Konstantinos Neanidis; Lida Kostadima; George Fountzilas; Nicholas Pavlidis
Journal:  Support Care Cancer       Date:  2006-02-25       Impact factor: 3.603

5.  Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor.

Authors:  Kaoru Irisa; Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Yukimasa Hatachi; Akiko Fukuhara; Yuichi Sakamori; Yung Hak Kim; Tadashi Mio; Michiaki Mishima
Journal:  Med Oncol       Date:  2010-12-07       Impact factor: 3.064

Review 6.  Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Li-na Tang; Ai-na He; Zan Shen; Feng Lin; Yang Yao
Journal:  Lung       Date:  2012-06-19       Impact factor: 2.584

7.  Targeted therapies in small cell lung cancer.

Authors:  Hong-Yang Lu; Xiao-Jia Wang; Wei-Min Mao
Journal:  Oncol Lett       Date:  2012-07-06       Impact factor: 2.967

8.  Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening.

Authors:  Rong Guo; Yuan Zhang; Xiao Li; Xinrui Song; Da Li; Yong Zhao
Journal:  J Mol Model       Date:  2016-05-17       Impact factor: 1.810

9.  A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer.

Authors:  Hongyang Lu; Luo Fang; Xiaojia Wang; Jufen Cai; Weimin Mao
Journal:  Mol Clin Oncol       Date:  2014-06-12

10.  Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study.

Authors:  Young Jin Yuh; Hyo Rak Lee; Sung Rok Kim
Journal:  Cancer Res Treat       Date:  2008-09-30       Impact factor: 4.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.